KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2025)

Biocryst Pharmaceuticals' Asset Writedowns and Impairment history spans 3 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 9500.0% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached $1.0 million, down 60.91%, while the annual FY2024 figure was $1.3 million, 12.79% down from the prior year.
  • Asset Writedowns and Impairment reached -$1.1 million in Q4 2025 per BCRX's latest filing, down from $30000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q3 2024 to a low of -$1.1 million in Q4 2025.
  • Average Asset Writedowns and Impairment over 3 years is $263454.5, with a median of $30000.0 recorded in 2025.
  • The largest YoY upside for Asset Writedowns and Impairment was 81600.0% in 2025 against a maximum downside of 9500.0% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $1.3 million in 2023, then plummeted by 100.84% to -$11000.0 in 2024, then tumbled by 9500.0% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Asset Writedowns and Impairment are -$1.1 million (Q4 2025), $30000.0 (Q3 2025), and $817000.0 (Q2 2025).